{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000014","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-08-04T11:05:35+00:00","discovered_at":"2026-08-04T11:10:03.447898+00:00","generated_at":"2026-08-04T11:10:21.198857+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio appoints Molly Carr as CMO; grants 430,000 stock options at $1.40/share","bullets":["Dr. Carr appointed CMO effective July 31, 2026, leading global clinical strategy for obesity and cardiometabolic pipeline.","She previously served as Clinical Head at Eli Lilly, overseeing insulin/glucagon portfolio including Phase 3 efsitora.","Employment terms: $470,000 base salary, 40% target bonus, severance provisions.","Inducement award: options to purchase 430,000 shares at $1.40, vesting 25% after one year then monthly over 3 years.","Company advancing IBIO-600 and IBIO-610 into next clinical phases."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000014","json":"https://secwatch.observer/filing/0001420720-26-000014.json","markdown":"https://secwatch.observer/filing/0001420720-26-000014.md","text":"https://secwatch.observer/filing/0001420720-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/0001420720-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:10:21.198857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}